Member Info for technick

Thanks Private

Thanks YB, does anyone understand the repercussions and reasoning behind this process?

It will move quickly once there is some trading volume... I can’t believe how little promotion there is. The odd interview with Proactive Investors but even those are not particularly dynamic. Come on guys, first go anywhere molecular device in the market being used by the DOD, first pharmacogenetic POC testing being done by the NHS, they just need to tell it as it is a little more!

Agree, I am down some £25k on this, not small change unfortunately. I still believe the product is needed and hope someone will pick it up and get it to market

Certainly needs some careful investigation depending on where the business ends up. As I said watching the share trading on the drop from 40p to below 5p I felt for those PIs who had lost a lot, perhaps most of their investments. I think some kind of Q&A session at the very least. From what I've been able to understand the FDA concern on liver toxicity should have been identified in the risk assessment given the drugs history with that regard and therefore should not have been overlooked since it would have been obvious that the FDA would want some assurance... Someone with more experience would be able to comment better...

I've held these for a long time. The product is needed, we are running out of effective antibiotics. It's a major issue. In my opinion it will get bought because of that need and the fact that there are few new antibiotics in development. Whether or not shareholders see the value or not is another matter. It was sad to see all the sells coming thorough on the day of the FDA announcement and to appreciate the losses those trades represented. I am sure in some instances it was peoples main 'punt' or savings. I hope the Board appreciate the real losses people have had here and do their best to get some value back to the ordinary shareholder.

Concepta was founded by Michael Catt and Zhang Zhi Gang, both previously worked for Unipath/Unilever and were involved in the development of the Clearblue ovulation product, a market leader for 20 years. This was was a big innovation in OTC diagnostics at the time… Take a look at https://patents.google.com/patent/US6403380. Clearblue was sold by Unilever to Inverness Medical/ALERE (now Abbott) in 2001 for 116 million euro. Concepta offer an advance over the Clearblue product and in my opinion represents a similar opportunity to sell to one of the majors once the performance is demonstrated. Whether is in in 12, 24 months or longer its value should be significantly greater than the current share price....

Nice application for Genedrive not only within the NHS but also world wide. Not sure what the sales price for the test is likely to be but the RNS suggests a market of 90k tests per year with new born babies requiring the test in the UK. Pharmacogenetic testing in 30 minutes at POC. This is a market first. Once this gets more exposure there is surely scope for other genetic predisposition tests.

Long term holder, first time poster. What a shame the share price is languishing where it is. It takes a long time for new technology to enter a market, particularly so in the consumer market where a customer won't necessarily understand the benefit or difference compared to the other longer established products and brands that sit along side it... My guess is the BOD will see this and will be looking for a different way to commercialise...